Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;22(10):958-964.
doi: 10.1111/hiv.13154. Epub 2021 Aug 8.

Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance

Pierre Frange  1   2   3 , Stephane Blanche  3   4 , Florence Veber  3 , Veronique Avettand-Fenoel  1   4   5
Affiliations
Free article

Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance

Pierre Frange et al. HIV Med. 2021 Nov.
Free article

Abstract

Objectives: Although widely recommended, data about dolutegravir efficacy in HIV-1-infected children/adolescents are scarce, limited to short-term follow-up and mainly extrapolated from studies in adults with good adherence to treatment. This study aimed to provide long-term data about the risk of virological failure (VF) and acquired genotypic resistance in children and adolescents receiving dolutegravir.

Methods: This retrospective monocentric study included 134 paediatric patients who received a dolutegravir-based regimen for ≥ 12 months in 2014-2020. Virological failure was defined as not achieving a plasma viral load (pVL) < 50 copies/mL within 3 months of dolutegravir initiation or as experiencing virological rebound ≥ 50 copies/mL.

Results: Most of the subjects were antiretroviral therapy-experienced (90.3%), naïve from integrase inhibitors (90.3%) and displayed virological suppression at baseline (63.4%). Their median (interquartile range, IQR) age was 12.0 (8.0-15.8) years. Genotypic susceptibility score of the new regimen was ≥ 2 in 96% of cases. Median (IQR) follow-up was 34 (22-50) months. Virological failure occurred in 43 people (32.1%), more frequently where the baseline pVL was ≥ 50 copies/mL (67.4% vs. 22.0%, P < 0.01). M184V/I mutations in the reverse transcriptase gene were newly detected in three people with VF. Resistance to dolutegravir (mutations G118R and E138A in the integrase gene) emerged in one adolescent (0.7% of subjects, 2.3% of those with VF).

Conclusions: Whereas VF is relatively common on dolutegravir in the paediatric population, regimens associating dolutegravir with more than one fully active drug were associated with a low rate of emergent drug resistance. This result strengthens the recommendation of dolutegravir as part of preferred combinations in children/adolescents.

Keywords: adolescents; children; dolutegravir; resistance; virological failure.

PubMed Disclaimer

References

REFERENCES

    1. Castro H, Judd A, Gibb DM, et al. Risk of triple-class failure in children with HIV: a retrospective cohort study. Lancet. 2011;377:1580-1587.
    1. Seng R, Bigna JJ, Faye A, et al. Poorer control of viral load in patients infected perinatally versus during adulthood. Abstract 0807. 26th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, 2019.
    1. Sigaloff KC, Calis JC, Geelen SP, et al. HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. Lancet Infect Dis. 2011;11:769-779.
    1. World Health Organization. HIV treatment. Update of recommendations on first- and second-line antiretroviral regimens. July 2019. Available at: https://www.who.int/hiv/pub/arv/arv-update-2019-policy/en/
    1. Briand C, Dollfus C, Faye A, et al. Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study. J Antimicrob Chemother. 2017;72:837-843.

Publication types

LinkOut - more resources